Herb-partitioned moxibustion alleviates colonic inflammation in Crohn's disease rats by inhibiting hyperactivation of the NLRP3 inflammasome via regulation of the P2X7R-Pannexin-1 signaling pathway.

Researchers in China investigated how herb-partitioned moxibustion might help treat Crohn's disease, a chronic inflammatory bowel condition that causes abdominal pain, severe diarrhea, and intestinal damage. In this treatment, herbs are placed on specific acupuncture points—Qihai (CV 6) on the lower abdomen and Tianshu (ST 25) near the navel—and then warming moxa is applied on top. Using a rat model of Crohn's disease, scientists examined whether this traditional technique could reduce intestinal inflammation and how it works at the cellular level. The study found that herb-partitioned moxibustion at these points significantly improved colon health by reducing inflammatory damage, preventing colon shortening, and lowering inflammation scores. The treatment appeared to work by blocking a specific inflammatory pathway involving the NLRP3 inflammasome, a protein complex that triggers inflammation when overactivated. The researchers discovered that moxibustion reduced levels of ATP and proteins called P2X7R and Pannexin-1, which ultimately decreased the release of inflammatory molecules like IL-1β and IL-18 that damage the intestinal lining. This is the first study to identify this particular mechanism for how moxibustion may benefit Crohn's disease. While these results are promising, it's important to note this was an animal study, and human clinical trials would be needed to confirm these benefits in people with Crohn's disease. The findings suggest moxibustion might offer a complementary approach to managing intestinal inflammation through specific biological pathways. Anyone interested in moxibustion for inflammatory bowel conditions should consult with a licensed acupuncturist trained in traditional Chinese medicine techniques.

This study investigated herb-partitioned moxibustion at CV 6 (Qihai) and ST 25 (Tianshu) in a rat model of Crohn's disease, focusing on the NLRP3 inflammasome pathway. Results demonstrated significant improvements in colon macroscopic damage indexes, histopathological scores, and colon length preservation. The mechanism of action was elucidated through measurement of ATP content and expression levels of P2X7R, Pannexin-1, NF-κBp65, NLRP3, ASC, caspase-1, IL-1β, and IL-18. Herb-partitioned moxibustion significantly inhibited ATP content and reduced expression of P2X7R and Pannexin-1, thereby blocking abnormal NLRP3 inflammasome activation and downstream inflammatory cytokine release. This represents the first identification of the P2X7R-Pannexin-1 signaling pathway as the mechanism through which moxibustion regulates NLRP3 inflammasome activity in Crohn's disease. Clinical implications suggest point-specific moxibustion may modulate intestinal inflammation through adenosine signaling pathways, though human trials are needed to validate therapeutic efficacy and optimal treatment protocols for inflammatory bowel disease management.